Skip to main content

Underactive Bladder

1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
2 programs
1
ASP8302Phase 21 trial
Direct Bladder Wall StimulationN/A
Active Trials
NCT03702777Completed135Est. Apr 2020
iota Biosciences
iota BiosciencesCA - Alameda
1 program
Direct Bladder Wall StimulationN/A1 trial
Active Trials
NCT06956209Recruiting15Est. Sep 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AstellasASP8302
iota BiosciencesDirect Bladder Wall Stimulation

Clinical Trials (2)

Total enrollment: 150 patients across 2 trials

A Study of ASP8302 in Participants With Underactive Bladder

Start: Nov 2018Est. completion: Apr 2020135 patients
Phase 2Completed
NCT06956209iota BiosciencesDirect Bladder Wall Stimulation

Akyva First In Human

Start: Sep 2025Est. completion: Sep 202815 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 150 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.